Navigation Links
FDA Approves New Drug to Fight Advanced Prostate Cancer

WEDNESDAY, May 15 (HealthDay News) -- The U.S. Food and Drug Administration announced Wednesday that it has approved a drug to help men with advanced prostate cancer whose disease has spread to the bones.

The drug, Xofigo, is targeted to patients with late-stage, metastatic disease that has spread to the bones but not to other organs, the FDA said in a news release. It is meant for patients who have already undergone surgery and/or drug therapies such as hormone-based treatments.

The FDA said Xofigo, marketed by Wayne, N.J.-based Bayer Pharmaceuticals, was approved more than three months ahead of the original August 2013 deadline the agency had set for a complete review. Instead, the drug was reviewed under the agency's "priority" review program, designated for medicines that appear safe and effective in a context where no good alternative therapy exists.

"Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, explained in the news release.

In a clinical trial involving more than 800 men with symptomatic prostate cancer that was resistant to hormonal therapy and had spread to the bones, men on Xofigo survived a median of 14 months compared to a little over 11 months for men taking a placebo. Side effects from Xofigo included nausea, diarrhea, vomiting and swelling of the legs and feet. Low levels of red and white blood cells, as well as platelets, were also reported among some patients taking Xofigo, the FDA said.

Pazdur noted that "Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer." The other drug, Xtandi, was approved by the FDA last August for men with hormone treatment-resistant prostate cancers that have spread or recurred, and who had previously been treated with the drug docetaxel.

According to the American Cancer Society, prostate cancer remains the leading cancer type among men outside of skin cancer, and about one man in every six will develop the illness during his lifetime. Caught early, it is often curable. About 239,000 new cases of prostate cancer are diagnosed among American men each year, and nearly 30,000 men die from the disease annually.

More information

Find out more about prostate cancer at the U.S. National Cancer Institute.

-- E.J. Mundell

SOURCES: May 15, 2013, news release, U.S. Food and Drug Administration; American Cancer Society

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Morning-After Pill Without a Prescription
2. FDA Approves New “Gummy Bear” Breast Implants, But Albany Plastic Surgeon Urges Caution
3. FDA Approves 1st in New Class of Type 2 Diabetes Drugs
4. FDA Approves New Multiple Sclerosis Drug
5. FDA Approves Drug for Older Women Experiencing Painful Sex
6. FDA Approves Bionic Eye to Help Against Rare Vision Disorder
7. MSSD Approves of the Encinitas School District’s Holistic Education
8. FDA Approves 3 New Drugs for Type 2 Diabetes
9. FDA Approves 1st Skin Patch to Combat Migraines
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves New Type of Flu Vaccine
Post Your Comments:
Related Image:
FDA Approves New Drug to Fight Advanced Prostate Cancer
(Date:11/30/2015)... ... , ... Scott Newman MD, FACS of New York’s Advanced ... in the New York City area to utilize the new, non-invasive SculpSure™ Laser ... treatment for fat loss in the abdomen, flanks, and other areas that is ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... GKhair & ... of the San Juan Beauty Show held on November 8th and 9th at the ... by media personalities, hair artists, renowned beauticians and top of the line fashion journalists. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... ), a leading provider of enterprise Time and Attendance/Workforce Management cloud-based ... in the Microsoft Partner Program with competencies in the Application Development, demonstrating ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... dealer. Joining more than 30 HealthPostures’ dealers located throughout the United States, is ... the number of corporate, industrial, manufacturing and government workers and organizational leaders that ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
(Date:11/30/2015)... 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... on December 3, 2015. TIME: 3:15p.m. ET ... ET LINK: --> DATE: ... --> --> ... are invited to ask the company questions in real-time - ...
(Date:11/30/2015)... Nuance Communications, Inc. (NASDAQ: NUAN ) and ... today jointly announced a new integrated set of clinical ... College of Radiology,s (ACR) Imaging 3.0™ tools to enable ... current and emerging value-based payment models . ... clinical decision support, radiology reporting and image sharing technology ...
Breaking Medicine Technology: